Amendment: SEC Form SC 13G/A filed by Immunovant Inc.
$IMVT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/10/2024 | $36.00 | Outperform | Raymond James |
| 10/9/2024 | $47.00 → $53.00 | Outperform | Oppenheimer |
| 3/28/2024 | $50.00 | Outperform | Oppenheimer |
| 3/13/2024 | $50.00 | Buy | Goldman |
| 2/20/2024 | $51.00 | Overweight | JP Morgan |
| 2/15/2024 | $55.00 | Outperform | Wolfe Research |
| 12/12/2023 | $50.00 | Buy | Deutsche Bank |
| 10/13/2023 | $18.00 → $55.00 | Neutral → Buy | UBS |
4 - Immunovant, Inc. (0001764013) (Issuer)
4 - Immunovant, Inc. (0001764013) (Issuer)
4 - Immunovant, Inc. (0001764013) (Issuer)
Raymond James resumed coverage of Immunovant Sciences with a rating of Outperform and set a new price target of $36.00
Oppenheimer reiterated coverage of Immunovant Sciences with a rating of Outperform and set a new price target of $53.00 from $47.00 previously
Oppenheimer initiated coverage of Immunovant Sciences with a rating of Outperform and set a new price target of $50.00
10-Q - Immunovant, Inc. (0001764013) (Filer)
8-K - Immunovant, Inc. (0001764013) (Filer)
8-K - Immunovant, Inc. (0001764013) (Filer)
Cantor Fitzgerald analyst Louise Chen reiterates Immunovant (NASDAQ:IMVT) with a Overweight.
Cantor Fitzgerald analyst Louise Chen reiterates Immunovant (NASDAQ:IMVT) with a Overweight.
Oppenheimer analyst Leland Gershell maintains Immunovant (NASDAQ:IMVT) with a Outperform and lowers the price target from $50 to $46.
Five Investigational New Drug (IND) applications cleared across a range of therapeutic areas and FDA divisions for lead asset, IMVT-1402Proof of concept data from batoclimab trial in Graves' disease (GD) demonstrate potential of deeper IgG reduction with potent FcRn inhibition to transform treatment for GD patients who are not well controlled on antithyroid drugs (ATDs); initiation of potentially registrational trial to evaluate IMVT-1402 in GD expected by year endIND cleared for IMVT-1402 in rheumatoid arthritis (RA), with potential best-in-class profile in difficult-to-treat (D2T) RA; initiation of potentially registrational trial to evaluate IMVT-1402 in D2T RA expected by March 31, 2025O
Completed enrollment in batoclimab pivotal Myasthenia Gravis (MG) trial; top-line results and initiation of a potentially registrational program for IMVT-1402 on track for fiscal year end (March 31, 2025) Progressed development of lead asset IMVT-1402 with 3 Investigational New Drug (IND) applications expected to be active by calendar year end (December 31, 2024)Progressed Graves' disease (GD) program and on track to disclose additional results from the batoclimab study in GD as well as an overview of our development program for IMVT-1402 in GD in the fall of 2024As of June 30, 2024, Immunovant's cash and cash equivalents totaled approximately $560 million NEW YORK, Aug. 06, 2024 (GLOB
Following a recently completed Type B meeting with the FDA, Immunovant is on track to initiate 4 to 5 potentially registrational studies for its lead asset IMVT-1402 in endocrinology, neurology, and other therapeutic areas over this fiscal year ending March 31, 2025Topline data from the batoclimab Myasthenia Gravis (MG) study is also expected over this fiscal year and further potentially registrational development in MG with IMVT-1402 is expected to begin in the same timeframeImmunovant has decided to run the batoclimab trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) longer prior to unblinding period 1 in order to better ensure that the data from the batoclimab trial, combi
Ankyra is pleased to announce the appointment of Dr. Julia G. Butchko and Ms. Tara Withington to the Board of Directors effective September 25, 2024. They will both serve as independent board members and their appointment brings the total board composition to seven directors. "We are delighted to welcome Dr. Butchko and Ms. Withington to the Board", stated Tillman Gerngross, PhD, Chairman of the Ankyra Board of Directors. "These accomplished individuals bring a fresh perspective to Ankyra at a critical time in the company's growth." Howard L. Kaufman, MD, President and Chief Executive Officer at Ankyra added "I am especially enthusiastic about working with Dr. Butchko and Ms. Withington sin
Mr. Levine adds valuable experience to the leadership team as Immunovant accelerates the development of batoclimab with the expected initiation of three pivotal trials in 2022 NEW YORK, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, announced the appointment of Mark Levine as Chief Legal Officer. "We are extremely pleased to welcome Mark Levine as Immunovant's Chief Legal Officer," said Pete Salzmann, M.D., Chief Executive Officer. "Mark's broad legal experience at biopharmaceutical companies ranging from early-stage development through commercialization wil
Ms. Barnett brings a wealth of financial experience to ImmunovantExpands executive leadership team as Immunovant plans to return to the clinic across multiple indications NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced the appointment of Renee Barnett, as Chief Financial Officer, effective October 4, 2021. "We are incredibly excited to have Renee Barnett join the Immunovant management team at this important time for our company," said Pete Salzmann, M.D., Chief Executive Officer. "Renee brings a deep understanding of drug developmen
Five Investigational New Drug (IND) applications cleared across a range of therapeutic areas and FDA divisions for lead asset, IMVT-1402Proof of concept data from batoclimab trial in Graves' disease (GD) demonstrate potential of deeper IgG reduction with potent FcRn inhibition to transform treatment for GD patients who are not well controlled on antithyroid drugs (ATDs); initiation of potentially registrational trial to evaluate IMVT-1402 in GD expected by year endIND cleared for IMVT-1402 in rheumatoid arthritis (RA), with potential best-in-class profile in difficult-to-treat (D2T) RA; initiation of potentially registrational trial to evaluate IMVT-1402 in D2T RA expected by March 31, 2025O
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that data from the Phase 2a trial of batoclimab in Graves' disease will be the subject of an oral presentation of a late-breaking abstract accepted for the 2024 American Thyroid Association (ATA) Annual Meeting being held October 30 to November 3, 2024, in Chicago, Illinois. New data highlighting both thyroid-specific and extrathyroidal manifestations of Graves' disease will be presented. Late-Breaking Oral Presentation Details: Title:Efficacy and Safety of the FcRn Inhibitor, Batoc
Ankyra is pleased to announce the appointment of Dr. Julia G. Butchko and Ms. Tara Withington to the Board of Directors effective September 25, 2024. They will both serve as independent board members and their appointment brings the total board composition to seven directors. "We are delighted to welcome Dr. Butchko and Ms. Withington to the Board", stated Tillman Gerngross, PhD, Chairman of the Ankyra Board of Directors. "These accomplished individuals bring a fresh perspective to Ankyra at a critical time in the company's growth." Howard L. Kaufman, MD, President and Chief Executive Officer at Ankyra added "I am especially enthusiastic about working with Dr. Butchko and Ms. Withington sin
SC 13G/A - Immunovant, Inc. (0001764013) (Subject)
SC 13G/A - Immunovant, Inc. (0001764013) (Subject)
SC 13G - Immunovant, Inc. (0001764013) (Subject)